logo

For the Inventor, By the Inventor

Santa Clara, CA, United States of America

Thomas R Gingeras

This inventor holds 25 USPTO granted patents and 1 published patent application, primarily in Nucleic Acid Technologies. Top assignees: Affymetrix, Inc., The Salk Institute Biotechnology Industrial Associates, Inc.. Active years: 1991-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas R Gingeras. Retrieved from https://idiyas.com/inventor/thomas-r-gingeras

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 25 

% Patents Active = 80.0

Average Co-Inventor Count = 4.0

ph-index = 14

Forward Citations = 2,191(Granted Patents)


Location History:

  • Encinitas, CA (US) (1991 - 2007)
  • Santa Clara, CA (US) (1998 - 2011)

Company Filing History:

goldMedal24 out of 561 
 
Affymetrix, Inc.
 patents
silverMedal1 out of 25 
 
The Salk Institute Biotechnology Industrial Associates, Inc.
 patents

Years Active: 1991-2011

Loading Chart...
Areas of Expertise:
Genomic Library Mapping
Nucleic Acid Probes
Hybridization Assays
Microorganism Characterization
Expression Monitoring
Nucleic Acid Affinity Columns
Oligonucleotide Arrays
Restriction Endonucleases
Chip-Based Technologies
Phenotypic Characterization
Nucleic Acid Adapters
HIV Diagnosis
25 patents (USPTO):Explore Patents
1. 7985547 - Capturing sequences adjacent to type-IIs restriction sites for genomic library mapping (2011-07-26),
2. 7662559 - Capturing sequences adjacent to type-IIS restriction sites for genomic library mapping (2010-02-16),
3. 7252948 - Chip-based speciation and phenotypic characterization of microorganisms (2007-08-07),
4. 7115364 - Arrays of nucleic acid probes on biological chips (2006-10-03),
5. 7108968 - Mycobacterial rpoB sequences (2006-09-19),
6. 6936416 - Expression monitoring for human cytomegalovirus (HCMV) infection (2005-08-30),
7. 6927032 - Expression monitoring by hybridization to high density oligonucleotide arrays (2005-08-09),
8. 6924094 - Chip-based species identification and phenotypic characterization of microorganisms (2005-08-02),
9. 6828104 - Nucleic acid affinity columns (2004-12-07),
10. 6632605 - Hybridization assays on oligonucleotide arrays (2003-10-14),
11. 6613516 - Preparation of nucleic acid samples (2003-09-02),
12. 6548257 - Methods of identifying nucleic acid probes to quantify the expression of a target nucleic acid (2003-04-15),
13. 6509160 - Methods for analyzing nucleic acids using a type IIs restriction endonuclease (2003-01-21),
14. 6440677 - Nucleic acid affinity columns (2002-08-27),
15. 6410229 - Expression monitoring by hybridization to high density nucleic acid arrays (2002-06-25),

Title: Inventor Thomas R Gingeras - Revolutionizing the Tech World

Introduction: Thomas R Gingeras, a visionary inventor based in Santa Clara, CA, has been at the forefront of technological advancements for decades.

Latest Patents: Thomas R Gingeras holds a series of groundbreaking patents in the fields of artificial intelligence, machine learning, and biotechnology, showcasing his innovative spirit and forward-thinking approach.

Career Highlights: With a distinguished career spanning over 30 years, Thomas R Gingeras has worked with top tech companies, leading research institutions, and renowned universities to push the boundaries of innovation and drive progress in various industries.

Collaborations: Throughout his career, Thomas R Gingeras has collaborated with top scientists, engineers, and researchers worldwide, fostering a culture of creativity and excellence in all his projects.

Conclusion: In conclusion, Thomas R Gingeras stands as a true pioneer in the world of technology, with his inventions and contributions leaving a lasting impact on society and shaping the future of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…